Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zhangyanming tablets plus sodium hyaluronate for dry eye disease
ChiCTR2200061479Phase 4Not yet recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of zhangyanming and sodium hyaluronate in dry eye syndrome (DED) (2 arms), sponsored by Zhongshan Ophthalmic Center. Primary endpoints: Tear film break-up time, Schirmer I test and 1 more. Planned start May 2022; status: not yet recruiting.
02
Drugs
zhangyanmingsodium hyaluronate
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on ChiCTR2200061479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061479.